|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Dalteparin#Use in Specific Populations]] |
| {{Dalteparin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use In Specific Populations==
| |
| | |
| ===Pregnancy===
| |
| | |
| '''''Pregnancy Category B'''''
| |
| | |
| There are no adequate and well-controlled studies of FRAGMIN use in pregnant women. In reproductive and developmental toxicity studies, pregnant rats and rabbits received dalteparin sodium at intravenous doses up to 2400 IU/kg (14,160 IU/m2) (rats) and 4800 IU/kg (40,800 IU/m2) (rabbits). These exposures were 2 to 4 times (rats) and 4 times (rabbits) the human dose of 100 IU/kg dalteparin based on the body surface area. No evidence of impaired fertility or harm to the fetuses occurred in these studies. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
| |
| | |
| Cases of "Gasping Syndrome" have occurred in premature infants when large amounts of benzyl alcohol have been administered (99-404 mg/kg/day). The 9.5 mL and the 3.8 mL multiple-dose vials of FRAGMIN contain 14 mg/mL of benzyl alcohol [see Warnings and Precautions (5.3)].
| |
| | |
| ===Nursing Mothers===
| |
| | |
| Based on limited published data dalteparin is minimally excreted in human milk. One study of 15 lactating women receiving prophylactic doses of dalteparin, in the immediate postpartum period, detected small amounts of anti-Xa activity (range < 0.005 to 0.037 IU/ml) in breast milk that were equivalent to a milk/plasma ratio of < 0.025-0.224. Oral absorption of LMWH is extremely low, but the clinical implications, if any, of this small amount of anticoagulant activity on a nursing infant are unknown. Caution should be exercised when Fragmin is administered to a nursing woman.
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness in pediatric patients have not been established.
| |
| | |
| ===Geriatric Use===
| |
| | |
| Of the total number of patients in clinical studies of FRAGMIN, 5516 patients were 65 years of age or older and 2237 were 75 or older. No overall differences in effectiveness were observed between these subjects and younger subjects. Some studies suggest that the risk of bleeding increases with age. Postmarketing surveillance and literature reports have not revealed additional differences in the safety of FRAGMIN between elderly and younger patients. Give careful attention to dosing intervals and concomitant medications (especially antiplatelet medications) in geriatric patients, particularly in those with low body weight (< 45 kg) and those predisposed to decreased renal function [see Warnings and Precautions (5) and Clinical Pharmacology (12)].
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = FRAGMIN (DALTEPARIN SODIUM) INJECTION [EISAI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c5cd4a8e-14c0-440b-b453-9f3d3250c951 | publisher = | date = | accessdate = 31 January 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Heparin group]]
| |
| [[Category:Anticoagulants]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |